Abstract Number: 2387 • 2019 ACR/ARP Annual Meeting
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has changed drastically in the last two decades in strategies and objectives, as well as in therapeutic options, especially…Abstract Number: 507 • 2019 ACR/ARP Annual Meeting
Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…Abstract Number: 543 • 2019 ACR/ARP Annual Meeting
Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients
Background/Purpose: Different types of cells play pathogenic roles in Rheumatoid Arthritis (RA). The immunogenetics of RA suggests a key role of aberrant pathways of T…Abstract Number: 991 • 2019 ACR/ARP Annual Meeting
Identification of Citrullinated Peptide Specific T-cells in Humanized Mice Immunized with Citrullinated Peptides
Background/Purpose: Seropositive rheumatoid arthritis (RA) is a T-cell mediated disease that is characterized by the presence of antibodies to proteins that have undergone the post-translational…Abstract Number: 1411 • 2019 ACR/ARP Annual Meeting
Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy
Background/Purpose: Rheumatoid arthritis (RA) occasionally overlaps Sjogren’s syndrome (SS), and RA patients with secondary SS have a higher disease activity of RA and worse joint…Abstract Number: 2009 • 2019 ACR/ARP Annual Meeting
Biomarkers Identified by Serum Inflammatory Profile Analysis to Predict Biologic Treatment Response in Rheumatoid Arthritis Patients
Background/Purpose: Biologic disease modifying antirheumatic drugs (b-DMARDs) have revolutionized the management of Rheumatoid Arthritis (RA). Despite this success, a high percentage of the patients undergoing…Abstract Number: 2401 • 2019 ACR/ARP Annual Meeting
Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate
Background/Purpose: Methotrexate (MTX) is an anti-folate prodrug activated to MTX polyglutamates (MTXPGs). Japanese Rheumatoid Arthritis (RA) patients are thought to have heightened sensitivity to MTX…Abstract Number: 508 • 2019 ACR/ARP Annual Meeting
Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, demonstrated efficacy and an acceptable safety profile in a Phase 2b study (RAJ1 study, NCT01649999) and…Abstract Number: 547 • 2019 ACR/ARP Annual Meeting
Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis
Background/Purpose: Long‑term prevention of structural joint damage is a key treatment goal in the management of RA1. Upadacitinib (UPA), a JAK1-selective inhibitor, inhibited the progression…Abstract Number: 995 • 2019 ACR/ARP Annual Meeting
Inhibition of Endoplasmic Reticulum Stress Using 4-phenylbutyric Acid Ameliorates the Severity of Collagen-induced Arthritis in Mice via Attenuation of Proliferation and Inflammatory Responses of Synovial Fibroblasts
Background/Purpose: Several studies have recently revealed the pathological role of endoplasmic reticulum (ER) stress in the pathogenesis of inflammatory diseases. In addition, 4-phenylbutyric acid (4-PBA) was…Abstract Number: 1423 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study
Background/Purpose: Early biologic use can improve long-term control of RA, and early use of abatacept (ABA) + MTX has demonstrated sustained improvements in selected patient-reported…Abstract Number: 2016 • 2019 ACR/ARP Annual Meeting
Expression of Peptidyl-arginine Deiminases in Peripheral Blood Neutrophils and Its Association with Single Nucleotide Variants in Patients with Rheumatoid Arthritis
Background/Purpose: Peptidyl-arginine deiminases (PADIs) are enriched in neutrophils and considered to be responsible for citrullination of proteins in vivo. Autoantibody against citrullinated proteins are frequently…Abstract Number: 2403 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in studies of Japanese, Korean and Taiwanese patients with RA. This analysis of…Abstract Number: 510 • 2019 ACR/ARP Annual Meeting
Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory condition associated with increased rates of atherosclerotic progression via pathogenic remodeling of high-density lipoprotein (HDL)-associated proteins, resulting…Abstract Number: 550 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study
Background/Purpose: Filgotinib (FIL) is an oral selective Janus kinase (JAK1) inhibitor. In studies to date, FIL has been shown to be effective and safe in…
- « Previous Page
- 1
- …
- 164
- 165
- 166
- 167
- 168
- …
- 188
- Next Page »